Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma


Por: Martínez-Pérez, LA, Latasa, MU, Uriarte, I, López-Pascual, A, Elurbide, J, Strnad, P, Frankova, S, Sticova, E, Fabian, O, Arechederra, M, Santamaria, E, Argemi, J, Sangro, B, Foglia, B, Parola, M, Gutiérrez-Angulo, M, Cairo, S, Bataller, R, Sancho-Bru, P, Martinez-Chantar, ML, Marin, JJG, Castaneda, A, Armengol, C, Berasain, C, Fernandez-Barrena, MG and Avila, MA

Publicada: 13 mar 2026
Resumen:
Background & Aims Hepatoblastoma (HB) is the most common malignant liver tumour in children. Despite improved survival in low-risk disease, outcomes for advanced or relapsed HB remain poor, emphasising the need for new therapeutic targets. Hypoxia, a hallmark of aggressive tumours, has recently been implicated in HB pathogenesis, but the molecular mechanisms involved are unclear. This study aimed to characterise the hypoxia-driven transcriptomic landscape of HB and identify key mediators of tumour progression.Methods Transcriptomic analyses of HB cell lines cultured under normoxic and hypoxic conditions were combined with bioinformatic interrogation of public HB datasets, immunohistochemistry of human and murine tumours and plasma ELISA assays. Functional roles of trefoil factor 3 (TFF3) were evaluated through overexpression and shRNA-mediated knockdown in vitro and in a beta-catenin/YAP-driven mouse model of HB.Results Hypoxia induced broad transcriptional reprogramming in HB cells, including significant upregulation of TFF3, a secreted oncogenic peptide. TFF3 expression was elevated in HB tissues and plasma, and colocalized with hypoxia marker carbonic anhydrase 9 (CA9). TFF3 promoted proliferation, anchorage-independent growth and cisplatin resistance under both normoxia and hypoxia. Knockdown of murine Tff3 suppressed tumour formation and angiogenesis in vivo. Transcriptomic and molecular analyses revealed that TFF3 sustains C-MYC expression and modulates mTOR/GSK3 beta signalling.Conclusions TFF3 is a hypoxia-inducible factor that enhances HB cell proliferation, survival and chemoresistance. Its tumour-promoting activity through C-MYC and mTOR pathways identifies TFF3 as a potential therapeutic target and circulating biomarker in hepatoblastoma.

Filiaciones:
Martínez-Pérez, LA:
 Univ Guadalajara, Ctr Univ Altos, Dept Ciencias Salud, Tepatitlan, Mexico

 Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain

Latasa, MU:
 Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain

 Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain

Uriarte, I:
 Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain

 CIBEREHD, Madrid, Spain

López-Pascual, A:
 Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain

 Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain

Elurbide, J:
 Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain

 CIBEREHD, Madrid, Spain

Strnad, P:
 Univ Hosp RWTH Aachen, Med Clin 3, Gastroenterol Metab Dis & Intens Care, Aachen, Germany

Frankova, S:
 Inst Clin & Expt Med, Dept Hepatogastroenterol, Prague, Czech Republic

Sticova, E:
 Inst Clin & Expt Med, Dept Hepatogastroenterol, Prague, Czech Republic

 Charles Univ Prague, Hosp Kralovske Vinohrady, Fac Med 3, Dept Pathol, Prague, Czech Republic

Fabian, O:
 Inst Clin & Expt Med, Dept Hepatogastroenterol, Prague, Czech Republic

 Charles Univ Prague, Thomayer Univ, Fac Med 3, Dept Pathol & Mol Med, Prague, Czech Republic

Arechederra, M:
 Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain

 Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain

 CIBEREHD, Madrid, Spain

Santamaria, E:
 CIBEREHD, Madrid, Spain

 Univ Navarra, RNA Biol & Therapeut Program, CIMA, CCUN, Pamplona, Spain

Argemi, J:
 Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain

 CIBEREHD, Madrid, Spain

 Univ Navarra, RNA Biol & Therapeut Program, CIMA, CCUN, Pamplona, Spain

Sangro, B:
 Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain

 CIBEREHD, Madrid, Spain

 Univ Navarra Clin, Liver Unit, CCUN, Pamplona, Spain

Foglia, B:
 Univ Torino, Dept Clin & Biol Sci, Unit Expt Med & Clin Pathol, Turin, Italy

Parola, M:
 Univ Torino, Dept Clin & Biol Sci, Unit Expt Med & Clin Pathol, Turin, Italy

Gutiérrez-Angulo, M:
 Univ Guadalajara, Ctr Univ Altos, Dept Ciencias Salud, Tepatitlan, Mexico

Cairo, S:
 Champ Oncol, Rockville, MD USA

Bataller, R:
 CIBEREHD, Madrid, Spain

 Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

Sancho-Bru, P:
 CIBEREHD, Madrid, Spain

 Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

Martinez-Chantar, ML:
 CIBEREHD, Madrid, Spain

 Basque Res & Technol Alliance, Ctr Cooperat Res Biosci CICbioGUNE, Liver Dis Lab, Bizkaia Sci & Technol Pk, Derio, Spain

Marin, JJG:
 CIBEREHD, Madrid, Spain

 Univ Salamanca, Expt Hepatol & Drug Targeting HEVEPHARM, IBSAL, Salamanca, Spain

:
 Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain

:
 CIBEREHD, Madrid, Spain

 Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain

Berasain, C:
 Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain

 CIBEREHD, Madrid, Spain

Fernandez-Barrena, MG:
 Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain

 Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain

 CIBEREHD, Madrid, Spain

Avila, MA:
 Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain

 Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain

 CIBEREHD, Madrid, Spain
ISSN: 14783231





Liver International
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Article
Volumen: 46 Número: 4
Páginas:
WOS Id: 001713798100001
ID de PubMed: 41823075
imagen Green Submitted, hybrid

MÉTRICAS